RT Journal Article SR Electronic T1 Transferability of genetic loci and polygenic scores for cardiometabolic traits in British Pakistanis and Bangladeshis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.22.21259323 DO 10.1101/2021.06.22.21259323 A1 Qin Qin Huang A1 Neneh Sallah A1 Diana Dunca A1 Bhavi Trivedi A1 Karen A. Hunt A1 Sam Hodgson A1 Samuel A. Lambert A1 Elena Arciero A1 Genes & Health Research team A1 John Wright A1 Chris Griffiths A1 Richard C. Trembath A1 Harry Hemingway A1 Michael Inouye A1 Sarah Finer A1 David A. van Heel A1 Thomas Lumbers A1 Hilary C. Martin A1 Karoline Kuchenbaecker YR 2021 UL http://medrxiv.org/content/early/2021/06/24/2021.06.22.21259323.abstract AB Background Individuals with South Asian ancestry have higher risk of heart disease than other groups in Western countries; however, most genetic research has focused on European-ancestry (EUR) individuals. It is unknown whether reported genetic loci and polygenic scores (PGSs) for cardiometabolic traits are transferable to South Asians, and whether PGSs have utility in clinical settings.Methods Using data from 22,000 British Pakistani and Bangladeshi individuals with linked electronic health records from the Genes & Health cohort (G&H), we conducted genome-wide association studies (GWAS) and characterised the genetic architecture of coronary artery disease (CAD), body mass index (BMI), lipid biomarkers and blood pressure. We applied a new technique to assess the extent to which loci from GWAS in EUR samples were transferable. We tested how well existing findings from EUR studies performed in genetic risk prediction and Mendelian randomisation in G&H.Results Trans-ancestry genetic correlations between G&H and EUR samples for the tested traits were not significantly lower than 1, except for BMI (rg=0.85, p=0.02). We found evidence for transferability for the vast majority of loci from EUR discovery studies that were sufficiently powered to replicate in G&H. PGSs showed variable transferability in G&H, with the relative accuracy compared to EUR (ratio of incremental r2/AUC) ≥0.95 for HDL-C, triglycerides, and blood pressure, but lower for BMI (0.78) and CAD (0.42). We observed significant improvement in categorical net reclassification in G&H (NRI=3.9%; 95% CI 0.9–7.0) when adding a previously developed CAD PGS to clinical risk factors (QRISK3). We used transferable loci as genetic instruments in trans-ancestry Mendelian randomisation and found evidence of an increased CAD risk for higher LDL-C and BMI, and for lower HDL-C in G&H, consistent with our findings for EUR samples.Conclusions The genetic loci for CAD and its risk factors are largely transferable from EUR studies to British Pakistanis and Bangladeshis, whereas the transferability of PGSs varies greatly between traits. Our analyses suggest clinical utility for addition of PGS to existing clinical risk prediction tools for this population.What is new?This is the first study to explore the transferability of GWAS findings and PGSs for CAD and related cardiometabolic traits in British Pakistani and Bangladeshi individuals from a cohort with real-world electronic clinical data.We propose a new approach to assessing transferability of GWAS loci between populations, which can serve as a new methodological standard in this developing field.We find evidence of overall high transferability of GWAS loci in British Pakistanis and Bangladeshis. BMI, lipids and blood pressure show the highest transferability of loci, and CAD the lowest.The transferability of PGSs varied between traits, being high for HDL-C, triglycerides and blood pressure but more modest for CAD, BMI and LDL-C.Our results suggest that, for some traits, the use of transferable GWAS loci improves the robustness of Mendelian randomisation estimates in non-Europeans.What are the clinical implications?The polygenic score for CAD derived from genetic studies of European individuals improves reclassification on top of clinical risk factors in British Pakistanis and Bangladeshis. The improvement was driven by identification of more cases in younger individuals (25–54 years old), and of controls in older individuals (55–84 years old).Incorporation of the polygenic score for CAD into risk prediction models is likely to prevent cardiovascular events and deaths in this population.Competing Interest StatementNS is now employed by GlaxoSmithKline.Funding StatementGenes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). This research was funded in part by the Wellcome Trust Grant 206194 to the Wellcome Sanger Institute. CG is supported by the National Institute for Health Research ARC North Thames. RTL and NS are supported by the BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074 and RTL is supported by a UK Research and Innovation Rutherford Fellowship hosted by Health Data Research UK (MR/S003754/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the London South East NRES Committee of the Health Research Authority (14/LO/1240).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenes & Heath imputed genotype data will be available on EGA (study accession number: EGAS00001005373). Researchers wishing to access phenotype data should apply to the G&H Executive (https://www.genesandhealth.org/research/scientists-using-genes-health-scientific-research). GWAS summary statistics generated in Genes & Health are available at https://www.genesandhealth.org/research/scientific-data-downloads. Publicly available GWAS summary statistics that were used in this study are provided in Supplementary Table S4.